Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | BRD4 | O60885 | 3/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103718 | 0.85 | KEAP1 (0.39) | CYP19A1HDAC8 | |
| SCHEMBL4135777 | 0.83 | HSD11B1 (0.33) | ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL2770249 | 0.80 | ALDH1A1 (0.47) | ALDH1A1BRD4LMNA | |
| SCHEMBL3153826 | 0.79 | ALDH1A1 (0.54) | ALDH1A1BRD4LMNACYP19A1 | |
| SCHEMBL2767456 | 0.79 | ALDH1A1 (0.48) | ALDH1A1BRD4KDM4EMRGPRX4SMPD1 | |
| SCHEMBL3329774 | 0.76 | ALDH1A1 (0.48) | ALDH1A1BRD4LMNAKDM4ECYP19A1 | |
| SCHEMBL2937209 | 0.73 | CA12 (0.40) | — | |
| SCHEMBL14124916 | 0.71 | CYP19A1 (0.43) | BRD4LMNAKDM4ECYP19A1SMPD1 | |
| SCHEMBL27720514 | 0.71 | ALDH1A1 (0.53) | ALDH1A1MRGPRX4 | |
| SCHEMBL27797837 | 0.71 | MEN1 (0.45) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229646-B2 | Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2022-01-25 | — | — | US | disclosed |
| US-20200330462-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-07 | — | — | US | disclosed |
| EP-3639824-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-04-22 | — | — | EP | disclosed |
| EP-3182973-B1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-09-18 | — | — | EP | disclosed |
| US-20170304301-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| EP-3182973-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016027249-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-02-25 | — | — | WO | disclosed |
| US-8389524-B2 | Tricyclic nitrogen containing compounds as antibacterial agents | GLAXO GROUP LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| EP-2137196-B1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-10-06 | — | — | EP | disclosed |
| EP-1963324-B1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2010-04-21 | — | — | EP | disclosed |
| EP-2167196-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | Glaxo Group Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| EP-2137196-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AS ANTIBACTERIAL AGENTS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| US-20090036433-A1 | Heterocyclic Compounds, their Preparation and their Use as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
| WO-2009000745-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | WO | disclosed |
| EP-2005995-A1 | Heterocyclic compounds for the treatment of tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | EP | disclosed |
| WO-2008128942-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| EP-1963324-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2008-09-03 | — | — | EP | disclosed |
| US-20070185153-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| WO-2007071936-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330462-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | NME2, NNMT, NGLY1 | ALDH1A1 2255/4885BRD4 2092/4885SLC6A9 2168/4885 |
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | DHPS, HSD17B11, GNE | ALDH1A1 300/4885BRD4 3655/4885SLC6A9 1522/4885 |
| US-20070185153-A1 | COMPOUNDS | NRDC, NISCH, MRPL21 | ALDH1A1 4225/4885BRD4 994/4885SLC6A9 2464/4885 |
| US-11229646-B2 | Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione | GMPS, GNE, DHPS | ALDH1A1 1200/4885BRD4 1800/4885SLC6A9 4042/4885 |
| US-20170304301-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | NME2, NNMT, NGLY1 | ALDH1A1 2255/4885BRD4 2092/4885SLC6A9 2168/4885 |
| US-20090036433-A1 | Heterocyclic Compounds, their Preparation and their Use as Antibacterials | MRPL21, NACA, NISCH | ALDH1A1 2482/4885BRD4 2542/4885SLC6A9 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.